Latest Breaking News On - Miguel ahuvi - Page 1 : comparemela.com

The Israeli clinical stage oncology drug developer has a share subscription facility of up to €20 million from Luxembourg-based GEM.

Loren beckerShmuel kabiliMiguel ahuviEurope vidacVidac pharmaMax herzbergLisrael biotech fundGlobal yieldKoronis foundationHamburg stock exchangeHamburg stockVidac sharesSepal pharmaBecker photo